Adial Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the development of treatments for addictions. The Company’s lead investigational new drug product, AD04, is currently in Phase 3 development as a genetically targeted therapeutic agent for the treatment of Alcohol Use Disorder (AUD). A Phase 2b clinical trial of AD04 for the treatment of AUD showed promising results in reducing frequency and quantity of drinking and heavy drinking with no overt safety concerns.
Genetically Targeted
Designed to reduce craving to effectively curb alcohol intake in those patients with the genetics expected to indicate a likely response to treatment with AD04
BRINGS 20+ YEAR TRACK RECORD OF CLINICAL USE
To date, clinical testing of AD04 has shown it to have a positive safety and tolerability profile with side effects similar to placebo.
Oral daily dosing
Our product candidate is intended to be easy to use since it is administered orally.
Media
Sorry, no posts matched your criteria.
AUD is characterized by an urge to consume alcohol and an inability to control the levels of consumption
Email Alerts
SIGN UP TODAYLatest Tweets
Tune in today at 3:15pm ET to hear our CEO @BillStilley present a Company overview at the #ICRConference2021! A live webcast will be available here:... $ADIL
23rd Annual ICR Conference
ir.adialpharma.com
Our CEO @BillStilley will present a Company overview at the #ICRConference2021 tomorrow, January 14, 2021 at 3:15pm-3:55pm ET. For webcast details: ...$ADIL
23rd Annual ICR Conference
bit.ly
We are pleased to announce our third patent for AD04 around Opioid Use Disorder. Per Adial Pharmaceuticals CEO Bill Stilley, "We see significant ...potential in AD04 for the treatment of Opioid Use Disorder since
AD04 Ready to Enter Phase 3 in Targeted Groups
Adial has commenced a Phase 3 clinical trial using AD04 for the potential treatment of AUD in subjects with certain target genotypes.
Adial has created an investigational attendant diagnostic biomarker blood test for the genetic screening of patients with certain biomarkers that, as reported in the American Journal of Psychiatry (Johnson, et. al. 2011 & 2013), Adial believes make patients more likely to benefit from treatment with AD04.
Adial’s strategy is to integrate pre-treatment genetic screening into AD04’s label to create a patient-specific treatment in one integrated therapeutic offering. Adial’s goal is to develop a genetically targeted, effective and safe product candidate to treat AUD that does not require abstinence as part of the treatment.